Senores Pharmaceuticals , a global research-driven pharmaceutical company, has reported robust financial results for the second quarter and half year ended September 30, 2025, showcasing significant growth across key metrics.

Financial Highlights

Quarterly Performance

• Consolidated revenue: Rs. 162.00 crores (61% year-on-year growth)
• Profit after tax: Rs. 30.00 crores (131% year-on-year increase)

Half-Year Performance

• Consolidated revenue: Rs. 300.00 crores (66% year-on-year growth)
• Profit after tax: Rs. 51.00 crores (114% year-on-year increase)

Segment Performance

Senores Pharmaceuticals' growth was primarily driven by strong performance across various segments:

• Regulated Markets: Revenue grew by 87% year-on-year in Q2
• Branded Generics: Revenues increased more than tenfold year-on-year

Cash Flow

The company generated Rs. 31.40 crores in operating cash flow for the half year, demonstrating improved financial efficiency.

Management Appointment

The board of Senores Pharmaceuticals approved the appointment of Mr. Manohar Lalge as President-Research and Development. Key details:

• Experience: Over 25 years in pharmaceutical formulation development
• Position: Categorized as Senior Management Personnel
• Effective Date: November 6, 2025

Future Outlook

With its robust financial performance, strategic appointments, and focus on key business segments, Senores Pharmaceuticals appears well-positioned for growth in both regulated and emerging pharmaceutical markets. The strong Q2 results and addition of experienced leadership in research and development signal a positive trajectory for the company in the coming quarters.

Senores Pharmaceuticals Limited has announced a significant development for its material subsidiary, Havix Group Inc. (operating as Aavis Pharmaceuticals). The company has successfully addressed and resolved all observations identified during a recent US Food and Drug Administration (FDA) inspection, leading to the receipt of an Establishment Inspection Report (EIR) on November 4, 2025.

Inspection Details

The FDA conducted an inspection of Havix's manufacturing facility located in Hoschton, Georgia, from July 21-25, 2025. The inspection resulted in three minor observations under Form 483. These observations have since been addressed and resolved by Havix, demonstrating the company's commitment to maintaining high-quality standards in its pharmaceutical manufacturing processes.

Implications for Senores Pharmaceuticals

The receipt of the EIR from the FDA is a positive development for Senores Pharmaceuticals and its US subsidiary. It indicates that the FDA is satisfied with the corrective actions taken by Havix in response to the observations made during the inspection. This outcome is crucial for maintaining the company's ability to manufacture and distribute pharmaceutical products in the United States market.

Additional Corporate Development

In a separate but related development, Senores Pharmaceuticals has also announced a strategic move to expand its presence in the US market. The company's wholly-owned subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into a Limited Liability Company Agreement (LLCA) dated November 04, 2025. Through this agreement, SPI has subscribed to 51% of the membership interest in Zoraya Pharmaceuticals, LLC, a newly formed entity in Delaware, USA.

Key Details of the New Subsidiary

This strategic move transforms Zoraya Pharmaceuticals, LLC into a step-down subsidiary of Senores Pharmaceuticals Limited, potentially strengthening the company's foothold in the US pharmaceutical market.

These developments collectively underscore Senores Pharmaceuticals' commitment to expanding its operations and maintaining regulatory compliance in the highly regulated US pharmaceutical market. The successful resolution of FDA observations and the formation of a new subsidiary may position the company for potential growth opportunities in the future.